Pharmaceutical Manufacturing Equipment Market Size - Global Forecast to 2028

1. MarketsandMarkets Presents Pharmaceutical Manufacturing Equipment Market Size - Global Forecast to 2028 Pharmaceutical Manufacturing Equipment Market by Equipment Type (Packaging, Mixing & Blending, Filling, Milling, Spray Drying, Inspection, Extrusion, Tablet Compression Presses), End-Product Type (Solid, Liquid) and Region - Global Forecast to 2028 https://www.marketsandmarkets.com/Market-Reports/pharmaceutical-manufacturing-equipment-market-268102519.html

2. The pharmaceutical manufacturing equipment market is estimated to be worth USD 14.5 billion in 2023 and is projected to reach USD 19.7 billion by 2028, at a CAGR of 6.3% during the forecast period. Growing global demand for generics, rising necessity for adoption of flexible pharmaceutical manufacturing practices, rising potential of pharmaceutical manufacturing infrastructure worldwide, and growing implementation of government schemes and regulatory frameworks for quality assurance are some of the major factors driving the market growth globally. Browse in-depth TOC on "Pharmaceutical Manufacturing Equipment Market" 191 – Tables49 – Figures224 – Pages

3. Packaging machines accounted for the largest share of the pharmaceutical manufacturing equipment market in 2022 The use of pharmaceutical packaging machines helps ensure that the final product is protected from contamination, damage, and degradation and meets the required specifications for labeling, dosage, and storage. The efficient and precise packaging of drug products is essential to ensure that they are safe and effective for patient use and to comply with regulatory requirements. With the increasing geriatric population, rising healthcare investment, and growing cases of chronic diseases across the world, the demand for diverse and innovative drugs is increasing, which in turn are driving Ask PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=268102519 Liquid end-product type segment to account for the largest share of the market during forecast period Liquid dosage forms are easier to swallow and more suitable for patients with difficulty swallowing tablets or capsules. They allow precise dosing, as the amount of drug in each dose can be easily measured and adjusted. This is particularly important for drugs with a narrow therapeutic range or requiring precise dosing. Liquid dosage forms provide greater flexibility in formulation, as drugs that are insoluble or unstable in solid dosage forms can be formulated as solutions or suspensions. Owing to these reasons, liquid dosage forms are preferred more over solid dosage forms, thereby driving their demand.

4. Asia Pacific held for the largest share of the pharmaceutical manufacturing equipment market in 2022 Asia Pacific is one of the fastest-growing and dynamically emerging pharmaceutical markets globally. Due to the low labor and manufacturing costs, the developing pharmaceutical manufacturing infrastructure, especially in India and China, has attracted many foreign investments from several pharma giants such as Uhlmann Group, Bausch+Ströbel, IMA S.p.A., and Marchesini Group. Moreover, governments across Asia are implementing schemes to boost local manufacturing capacity, expand generic drug production, and enhance quality assurance by establishing stringent regulations to meet global standards. Request Free Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=268102519 Key Market Players The major players in the pharmaceutical manufacturing equipment Companies include GEA Group Aktiengesellschaft (Germany), I.M.A. INDUSTRIA MACCHINE AUTOMATICHE S.P. A (Italy), Syntegon Technology GmbH (Germany), ACG (India), and Thermo Fisher Scientific Inc.(US). These companies have used both organic and inorganic growth strategies such as product launches, acquisitions, and partnerships to strengthen their position in the market.

5. Opportunity: Adoption of pharmaceutical manufacturing equipment to enable first-to-market advantages Rapidly growing demand for drugs and injectables has triggered competition among manufacturers to expedite the development and review pathways to reduce the demand and supply gap. In the pharmaceutical industry, there are many first-to-market benefits spanning across different market contexts and are more evident in cases of specialty areas with a small number of patients and prescribers and when the first mover is a well-established pharmaceutical manufacturer with experience in the product’s therapeutic area. Traditionally, pharmaceutical manufacturing has been executed through a combination of multiple facilities to perform different processes across the supply chain. But, as the competition to increase the speed to market has intensified, the project delays occurring due to transfers between different manufacturing sites are negatively hampering the manufacturers. This emphasizes the utilization of modern and advanced pharmaceutical manufacturing equipment, especially in modular setups, to enable the manufacturing of pharmaceuticals from one single diverse facility encompassing all supply chain processes. The use of modern pharmaceutical manufacturing equipment is helping manufacturers to cut down on lead times. Challenge:  Rising costs and expenditures related to usage of pharmaceutical manufacturing equipment Pharmaceutical manufacturing equipment must comply with strict regulations and guidelines set by government agencies, such as the EMA and FDA. Adhering to multiple regulations and standards is a time-consuming process and increases capital expenditures. In addition, pharmaceutical manufacturing equipment is often expensive to purchase, operate, and maintain. The high upfront costs related to adherence to regulations and maintenance can hinder innovation and product development. They also threaten the entry of emerging or smaller players to enter the market. Moreover, to cater to the ever-changing market demand in the pharmaceutical industry, manufacturing equipment needs to be constantly evolving. It needs regular upgrades, which involves additional costs for pharmaceutical manufacturers. This poses a significant challenge for pharmaceutical players to adopt and maintain various pharmaceutical manufacturing equipment.

6. About MarketsandMarkets MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions. Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations early to the market by providing them research ahead of the curve. MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of markets.

7. Contact Us Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA : 1-888-600-6441 For More Info: https://www.marketsandmarkets.com/PressReleases/pharmaceutical-manufacturing-equipment.asp